Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
2 hedge funds and large institutions have $12.1K invested in Eagle Pharmaceuticals, Inc. in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
69% less capital invested
Capital invested by funds: $38.8K → $12.1K (-$26.7K)
78% less funds holding
Funds holding: 9 → 2 (-7)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$11.8K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$9K |
| 3 |
Barclays
London,
United Kingdom
|
-$7.12K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$1.71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SLG
1
Stanley-Laman Group
Berwyn,
Pennsylvania
| $11.8K | – | – | – |
|
|
AIC
2
Archer Investment Corporation
Carmel,
Indiana
| $343 | – | – | – |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| – | -$11.8K | -23,594 | Closed |
|
|
4
Simplex Trading
Chicago,
Illinois
| – | -$9K | -18,162 | Closed |
|
|
5
Barclays
London,
United Kingdom
| – | -$7.12K | -14,233 | Closed |
|
|
6
Acadian Asset Management
Boston,
Massachusetts
| – | -$3K | -7,155 | Closed |
|
|
7
Russell Investments Group
London,
United Kingdom
| – | -$1.71K | -3,411 | Closed |
|
8
Credit Agricole
Montrouge Cedex,
France
| – | -$18 | -36 | Closed |
|
|
FFA
9
Farther Finance Advisors
San Francisco,
California
| – | -$18 | -35 | Closed |
|
EGRX Hedge Fund Activity: Q1 2025 in Review
2 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2025, worth a combined $12.1K — down 69% from $38.8K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of EGRX and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was XTX Topco, exiting entirely with an estimated $11.8K sold.
- 2 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2025, down from 9 in Q4 2024.
- Funds reported $12.1K of Eagle Pharmaceuticals, Inc. stock for Q1 2025, down 69% quarter-over-quarter.
- 0 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2025 and 7 closed out, a net change of -7 holders.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2025 was XTX Topco, an estimated $11.8K sold.
Based on aggregated 13F filings for Q1 2025.